A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.

导出 LinkOut

翻译打印收藏纠错

作者： Tobias,Derfuss ^[1] ; François,Curtin ^[2] ; Claudia,Guebelin ^[1] ; Claire,Bridel ^[3] ; Maria,Rasenack ^[1] ; Alain,Matthey ^[4] ; Renaud,Du Pasquier ^[5] ; Myriam,Schluep ^[5] ; Jules,Desmeules ^[4] ; Alois B,Lang ^[6] ; Hervé,Perron ^[6] ; Raphael,Faucard ^[6] ; Hervé,Porchet ^[7] ; Hans-Peter,Hartung ^[8] ; Ludwig,Kappos ^[1] ; Patrice H,Lalive ^[9]

作者单位： Neurology Department, Basel University Hospital, Switzerland. ^[1] GeNeuro SA, Switzerland fc@geneuro.com. ^[2] Department of Clinical Neurosciences, Geneva University Hospital, Switzerland. ^[3] Pharmacology and Toxicology Division, Geneva University Hospital, Switzerland. ^[4] Neurology Department, Lausanne University Hospital, Switzerland. ^[5] GeNeuro SA, Switzerland. ^[6] GeNeuro SA, Switzerland/Pharmacology Department, University of Pretoria, South Africa. ^[7] Neurology Department, Heinrich Heine University, Germany. ^[8] Department of Clinical Neurosciences, Geneva University Hospital, Switzerland/Department of Genetic and Laboratory Medicine, Geneva University Hospital, Switzerland/Department of Pathology and Immunology, University of Geneva, Switzerland. ^[9]

关键词 Multiple sclerosis clinical trial endogenous retrovirus human endogenous retrovirus type W family monoclonal antibody multiple sclerosis-associated retrovirus